Association of circulating factor seven activating protease (FSAP) and of oral Omega-3 fatty acids supplements with clinical outcome in patients with atrial fibrillation: the OMEGA-AF study

作者：Parahuleva Mariana S^*; Kanse Sandip; Hoelschermann Hans; Zheleva Kirila; Zandt Daniel; Worsch Michael; Parviz Behnoush; Guettler Norbert; Tillmanns Harald; Boening Andreas; Erdogan Ali

来源：Journal of Thrombosis and Thrombolysis, 2014, 37(3): 317-325.

DOI：10.1007/s11239-013-0921-0

• FSAP
• Atrial fibrillation
• Omega-3 fatty acid
• Inflammation
• Atrial remodelling
• Thrombogenesis

Factor VII Activating Protease (FSAP) activates factor VII (FVII) as well as pro-urokinase (uPA). Our goal was to evaluate the relation between plasma levels of FSAP and clinical instability in atrial fibrillation (AF) and possible effects of oral omega-3 fatty acids (FA) supplements. 101 patients with persistent AF were analyzed in the OMEGA-AF Study. Plasma FSAP levels were measured at baseline and after 12 weeks of treatment with omega-3 FA. The median FSAP antigen concentration, in contrast to FSAP activity, was higher in patients with persistent AF. The maintenance of SR after successful cardioversion (CV) did not lead to a normalization of FSAP concentration. Supplementation with omega-3 FA but not placebo significantly reduced elevated FSAP concentration. Furthermore, elevated FSAP levels did not indicate a significantly increased risk of recurrence of AF after electrical CV or cardiovascular clinical events during 1 year of follow-up. Plasma FSAP concentration was increased in patients with AF and may be involved in the pathogenesis of this condition. The possible effects of omega-3 FA on clinical AF potential could be linked with modulation of circulating FSAP levels.

• 出版日期2014-4